menu
    • menu
    [{"orgOrder":0,"company":"Precirix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Inapplicable"},{"orgOrder":0,"company":"Precirix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compounds","year":"2021","type":"Inapplicable","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Inapplicable"},{"orgOrder":0,"company":"Precirix","sponsor":"INKEF Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Radiolabeled Compounds","year":"2022","type":"Series B Financing","leadProduct":"Cam-H2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ INKEF Capital","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ INKEF Capital"},{"orgOrder":0,"company":"Precirix","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Partnership","leadProduct":"131-I Conjugated Anti-HER2 sdAb 2Rs15d","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precirix","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Precirix \/ Precirix","highestDevelopmentStatusID":"7","companyTruncated":"Precirix \/ Precirix"}]

    Find Clinical Drug Pipeline Developments & Deals by Precirix

    Menu

    Precirix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : INKEF Capital

                            Deal Size : $87.8 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Precirix Raises EUR 80m in Series B to Advance Its Pipeline of Precision Radiopharmaceuticals

                            Details : The proceeds of this financing round will fund the development and expansion of Precirix’ pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the ...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Undisclosed

                            March 16, 2022

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : INKEF Capital

                            Deal Size : $87.8 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Precirix Dosed First Patients in Phase I/II Clinical Study Evaluating CAM-H2 in HER2-Positive Metastatic Cance...

                            Details : CAM-H2 comprises a single-domain antibody targeting HER2, covalently linked to iodine-131. Single-domain antibodies are ideally suited for targeted delivery of radiation to tumors given their size for the treatment of HER2-positive metastatic cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            June 10, 2021

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Conjugated Anti-HER2 sdAb 2Rs15d

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Evergreen Theragnostics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Precirix Partners with Evergreen to Expand North American Clinical Trial Supply

                            Details : Under the terms of the deal, Evergreen will provide US-based manufacturing for Precirix’s lead product candidate, CAM-H2. CAM-H2 is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Undisclosed

                            April 28, 2021

                            Lead Product(s) : 131-I Conjugated Anti-HER2 sdAb 2Rs15d

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Evergreen Theragnostics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            July 13, 2020

                            Lead Product(s) : Cam-H2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed

                            Precirix

                            Belgium arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I SGMIB Anti-HER2 VHH1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            February 17, 2016

                            Lead Product(s) : 131-I SGMIB Anti-HER2 VHH1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth